1. Home
  2. BLNK vs XFOR Comparison

BLNK vs XFOR Comparison

Compare BLNK & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLNK
  • XFOR
  • Stock Information
  • Founded
  • BLNK 2009
  • XFOR 2014
  • Country
  • BLNK United States
  • XFOR United States
  • Employees
  • BLNK N/A
  • XFOR N/A
  • Industry
  • BLNK Industrial Specialties
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BLNK Consumer Discretionary
  • XFOR Health Care
  • Exchange
  • BLNK Nasdaq
  • XFOR Nasdaq
  • Market Cap
  • BLNK 119.2M
  • XFOR 118.4M
  • IPO Year
  • BLNK N/A
  • XFOR N/A
  • Fundamental
  • Price
  • BLNK $1.12
  • XFOR $1.82
  • Analyst Decision
  • BLNK Buy
  • XFOR Strong Buy
  • Analyst Count
  • BLNK 8
  • XFOR 3
  • Target Price
  • BLNK $2.54
  • XFOR $72.33
  • AVG Volume (30 Days)
  • BLNK 4.0M
  • XFOR 1.6M
  • Earning Date
  • BLNK 08-07-2025
  • XFOR 08-07-2025
  • Dividend Yield
  • BLNK N/A
  • XFOR N/A
  • EPS Growth
  • BLNK N/A
  • XFOR N/A
  • EPS
  • BLNK N/A
  • XFOR 2.16
  • Revenue
  • BLNK $109,383,000.00
  • XFOR $31,364,000.00
  • Revenue This Year
  • BLNK N/A
  • XFOR $1,300.08
  • Revenue Next Year
  • BLNK $31.15
  • XFOR N/A
  • P/E Ratio
  • BLNK N/A
  • XFOR $0.84
  • Revenue Growth
  • BLNK N/A
  • XFOR N/A
  • 52 Week Low
  • BLNK $0.63
  • XFOR $1.38
  • 52 Week High
  • BLNK $3.52
  • XFOR $26.96
  • Technical
  • Relative Strength Index (RSI)
  • BLNK 60.14
  • XFOR 44.64
  • Support Level
  • BLNK $0.92
  • XFOR $1.38
  • Resistance Level
  • BLNK $1.27
  • XFOR $2.25
  • Average True Range (ATR)
  • BLNK 0.08
  • XFOR 0.18
  • MACD
  • BLNK 0.02
  • XFOR 0.10
  • Stochastic Oscillator
  • BLNK 58.90
  • XFOR 50.57

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: